IRIS Accounts Production v24.1.4.33 02455978 Board of Directors 1.1.23 31.12.23 31.12.23 false true false false true false Fair value model iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh024559782022-12-31024559782023-12-31024559782023-01-012023-12-31024559782021-12-31024559782022-01-012022-12-31024559782022-12-3102455978ns15:EnglandWales2023-01-012023-12-3102455978ns14:PoundSterling2023-01-012023-12-3102455978ns10:Director12023-01-012023-12-3102455978ns10:PrivateLimitedCompanyLtd2023-01-012023-12-3102455978ns10:SmallEntities2023-01-012023-12-3102455978ns10:AuditExempt-NoAccountantsReport2023-01-012023-12-3102455978ns10:SmallCompaniesRegimeForDirectorsReport2023-01-012023-12-3102455978ns10:SmallCompaniesRegimeForAccounts2023-01-012023-12-3102455978ns10:FullAccounts2023-01-012023-12-3102455978ns10:Director22023-01-012023-12-3102455978ns10:CompanySecretary12023-01-012023-12-3102455978ns10:RegisteredOffice2023-01-012023-12-3102455978ns5:CurrentFinancialInstruments2023-12-3102455978ns5:CurrentFinancialInstruments2022-12-3102455978ns5:ShortLeaseholdAssetsns5:LandBuildings2023-01-012023-12-3102455978ns5:FurnitureFittings2023-01-012023-12-3102455978ns5:ComputerEquipment2023-01-012023-12-3102455978ns5:LandBuildings2022-12-3102455978ns5:ShortLeaseholdAssetsns5:LandBuildings2022-12-3102455978ns5:FurnitureFittings2022-12-3102455978ns5:ComputerEquipment2022-12-3102455978ns5:LandBuildings2023-01-012023-12-3102455978ns5:LandBuildings2023-12-3102455978ns5:ShortLeaseholdAssetsns5:LandBuildings2023-12-3102455978ns5:FurnitureFittings2023-12-3102455978ns5:ComputerEquipment2023-12-3102455978ns5:LandBuildings2022-12-3102455978ns5:ShortLeaseholdAssetsns5:LandBuildings2022-12-3102455978ns5:FurnitureFittings2022-12-3102455978ns5:ComputerEquipment2022-12-3102455978ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-12-3102455978ns5:CurrentFinancialInstrumentsns5:WithinOneYear2022-12-3102455978ns10:Director222022-12-3102455978ns10:Director222021-12-3102455978ns10:Director222023-01-012023-12-3102455978ns10:Director222022-01-012022-12-3102455978ns10:Director222023-12-3102455978ns10:Director222022-12-31
REGISTERED NUMBER: 02455978 (England and Wales)




















UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2023

FOR

HEALTH & BEAUTY PHARMACY LIMITED

HEALTH & BEAUTY PHARMACY LIMITED (REGISTERED NUMBER: 02455978)

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023










Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


HEALTH & BEAUTY PHARMACY LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 31 DECEMBER 2023







DIRECTORS: A Gautama
S Gautama



SECRETARY: A Gautama



REGISTERED OFFICE: 50 Seymour Street
London
W1H 7JG



REGISTERED NUMBER: 02455978 (England and Wales)



ACCOUNTANTS: Orcom Civvals Limited
Accountants
50 Seymour Street
London
W1H 7JG



BANKERS: Barclays Bank plc
Chiltern House
12 Station Approach
Gerrards Cross
Buckinghamshire
SL9 8PP

HEALTH & BEAUTY PHARMACY LIMITED (REGISTERED NUMBER: 02455978)

BALANCE SHEET
31 DECEMBER 2023

2023 2022
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 1,192,762 1,212,587
Investment property 5 1,025,000 1,025,000
2,217,762 2,237,587

CURRENT ASSETS
Stocks 341,181 353,058
Debtors 6 1,017,705 1,015,108
Cash at bank and in hand 2,074,743 2,054,974
3,433,629 3,423,140
CREDITORS
Amounts falling due within one year 7 173,185 224,307
NET CURRENT ASSETS 3,260,444 3,198,833
TOTAL ASSETS LESS CURRENT
LIABILITIES

5,478,206

5,436,420

PROVISIONS FOR LIABILITIES 237,163 216,369
NET ASSETS 5,241,043 5,220,051

CAPITAL AND RESERVES
Called up share capital 250 250
Fair value reserve 8 511,194 531,702
Capital redemption reserve 8 250 250
Revaluation reserve 8 585,708 585,708
Retained earnings 8 4,143,641 4,102,141
SHAREHOLDERS' FUNDS 5,241,043 5,220,051

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2023 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

HEALTH & BEAUTY PHARMACY LIMITED (REGISTERED NUMBER: 02455978)

BALANCE SHEET - continued
31 DECEMBER 2023


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 27 June 2024 and were signed on its behalf by:





S Gautama - Director


HEALTH & BEAUTY PHARMACY LIMITED (REGISTERED NUMBER: 02455978)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023


1. STATUTORY INFORMATION

Health & Beauty Pharmacy Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention as modified by the revaluation of certain assets.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Short leasehold - over the term of the lease
Fixtures and fittings - 15% on reducing balance
Computer equipment - 25% on reducing balance

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

HEALTH & BEAUTY PHARMACY LIMITED (REGISTERED NUMBER: 02455978)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2023


2. ACCOUNTING POLICIES - continued

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Investment properties
Investment properties are included at fair value. Revaluation surpluses are recognised in the income statement. Deferred taxation is provided on these gains at the rate expected to apply when properties are sold.

Going concern
The directors believe that the company is well placed to manage its business risks successfully despite the current uncertain economic outlook.

The directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Accordingly, they continue to adopt the going concern basis in preparing the annual report and accounts.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 11 (2022 - 10 ) .

4. TANGIBLE FIXED ASSETS
Fixtures
Freehold Short and Computer
property leasehold fittings equipment Totals
£    £    £    £    £   
COST OR VALUATION
At 1 January 2023
and 31 December 2023 1,200,000 73,955 223,487 10,700 1,508,142
DEPRECIATION
At 1 January 2023 - 69,684 216,691 9,180 295,555
Charge for year 18,000 426 1,019 380 19,825
At 31 December 2023 18,000 70,110 217,710 9,560 315,380
NET BOOK VALUE
At 31 December 2023 1,182,000 3,845 5,777 1,140 1,192,762
At 31 December 2022 1,200,000 4,271 6,796 1,520 1,212,587

HEALTH & BEAUTY PHARMACY LIMITED (REGISTERED NUMBER: 02455978)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2023


4. TANGIBLE FIXED ASSETS - continued

Cost or valuation at 31 December 2023 is represented by:

Fixtures
Freehold Short and Computer
property leasehold fittings equipment Totals
£    £    £    £    £   
Valuation in 2022 693,894 - - - 693,894
Cost 506,106 73,955 223,487 10,700 814,248
1,200,000 73,955 223,487 10,700 1,508,142

5. INVESTMENT PROPERTY

In the opinion of the director, Mr A Gautama, the book value of the investment property was a fair reflection of the market value of the investment property at the balance sheet date.

Fair value at 31 December 2023 is represented by:
£   
Valuation in 2012 406,877
Valuation in 2014 150,000
Valuation in 2021 80,788
Cost 387,335
1,025,000

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Trade debtors 66,237 66,946
Other debtors 5,277 -
Amount due from related
company 928,125 928,125
Prepayments 18,066 20,037
1,017,705 1,015,108

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Trade creditors 110,531 125,976
Tax 18,216 50,870
Social security and other taxes - 9,979
Directors' current account 13,976 16,108
Accrued expenses 30,462 21,374
173,185 224,307

HEALTH & BEAUTY PHARMACY LIMITED (REGISTERED NUMBER: 02455978)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2023


8. RESERVES
Fair Capital
Retained value redemption Revaluation
earnings reserve reserve reserve Totals
£    £    £    £    £   

At 1 January 2023 4,102,141 531,702 250 585,708 5,219,801
Profit for the year 20,992 20,992
Unrealised fair value gain 20,508 (20,508 ) - - -
At 31 December 2023 4,143,641 511,194 250 585,708 5,240,793

9. DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to a director subsisted during the years ended 31 December 2023 and 31 December 2022:

2023 2022
£    £   
A Gautama
Balance outstanding at start of year (16,108 ) (23,466 )
Amounts advanced 2,640 8,232
Amounts repaid (508 ) (874 )
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year (13,976 ) (16,108 )

10. RELATED PARTY DISCLOSURES

Included in debtors, is an amount of £928,125 (2022: £928,125) owed by a company under common directorship.